148148-48-5

Basic information

• Product Name: BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)PIPERIDINE-1-CARBOXYLATE
• Synonyms: BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)PIPERIDINE-1-CARBOXYLATE;1-CBZ-4-(METHOXY-METHYL-CARBAMOYL)-PIPERIDINE;4-(METHOXY-METHYL-CARBAMOYL)-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER;1-Cbz-N-Methoxy-N-Methyl-4-piperidinecarboxaMide
• CAS NO: 148148-48-5
• Molecular Formula: C₁₆H₂₂N₂O₄
• Molecular Weight: 306.36
• Mol File: 148148-48-5.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 422.1±55.0 °C(Predicted)
• Appearance: /
• Density: 1.191±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -2.36±0.40(Predicted)
• CAS DataBase Reference: BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)PIPERIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)PIPERIDINE-1-CARBOXYLATE(148148-48-5)
• EPA Substance Registry System: BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)PIPERIDINE-1-CARBOXYLATE(148148-48-5)

Safety Data

• Hazardous Substances Data: 148148-48-5(Hazardous Substances Data)

Usage

General Description

Benzyl 4-(N-methoxy-N-methylcarbamoyl)piperidine-1-carboxylate is a chemical compound that is often used in the field of organic chemistry and pharmaceutical research. It is a piperidine derivative, which means it contains a five-membered nitrogen-containing ring structure. The benzyl group attached to the piperidine ring adds additional complexity and versatility to the compound's chemical properties. BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)PIPERIDINE-1-CARBOXYLATE has potential applications in the development of new drugs and pharmaceuticals, as well as in the synthesis of other organic molecules. Its specific structure and properties make it a valuable building block for creating new chemical compounds with various uses.

Upstream product

• 1068-55-9 isopropylmagnesium chloride 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 160809-38-1 1-benzyl 4-ethyl piperidine-1,4-dicarboxylate 
• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 10314-99-5 benzyl 4-(chlorocarbonyl)piperidine-1-carboxylate 
• 501-53-1 benzyl chloroformate 
• 498-94-2 isonipecotic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 

Downstream Products

• 160809-34-7 4-acetyl-piperidine-1-carboxylic acid benzyl ester 
• 188345-20-2 4-propionyl-piperidine-1-carboxylic acid benzyl ester 
• 138163-08-3 N-(benzyloxycarbonyl)piperidine-4-carboxaldehyde 
• 184289-85-8 benzyl spiro[indole-3,4'-piperidine]-1'-carboxylate 
• 816464-65-0 3-[(2,4-difluorophenyl)amino]-7-phenyl-2-(piperidin-4-ylcarbonyl)-thieno[2,3-b]pyridin-6(7H)-one 
• 816464-49-0 benzyl 4-[(3-bromo-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl)carbonyl]piperidine-1-carboxylate 
• 816464-48-9 benzyl 4-[(3-amino-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl)carbonyl]piperidine-1-carboxylate 
• 816464-50-3 benzyl 4-({3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl}carbonyl)piperidine-1-carboxylate 
• 816464-47-8 benzyl 4-(2-bromoacetyl)piperidine-1-carboxylate 
• 455267-29-5 4-(1-amino-ethyl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

A pharmaceutical intermediate of PROTAC molecules targeting monoacylglycerol lipase. Preparation method and application

The invention discloses a medical intermediate of PROTAC molecules targeting monoacylglycerol lipase, a preparation method and an application thereof, and relates to the field of medicines. It has the structure shown I: formula I. The hydroxyl end has the

Renin Inhibitors

Disclosed are compounds having the formula (I): wherein the R1, R2, R3, X, Y, A, L, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.

RENIN INHIBITORS

Disclosed are compounds of Formula (I) wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.